Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGTNASDAQ:GHNASDAQ:RDNTNASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$20.12+2.1%$17.87$14.57▼$25.11$612.53M1270,380 shs406,012 shsGHGuardant Health$41.66-0.1%$43.70$20.14▼$52.92$5.16B1.492.21 million shs2.23 million shsRDNTRadNet$57.03+2.3%$50.85$45.00▼$93.65$4.28B1.46671,070 shs1.15 million shsVCYTVeracyte$30.76+3.5%$31.00$19.73▼$47.32$2.33B2.14882,049 shs1.08 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics+2.92%+2.86%+5.89%+23.66%-7.49%GHGuardant Health-0.14%-5.43%-4.69%-4.45%+86.23%RDNTRadNet+2.26%+7.34%+6.78%-7.69%+3.22%VCYTVeracyte+4.73%-1.79%-3.27%-24.92%+43.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLGTFulgent Genetics3.3849 of 5 stars2.31.00.04.12.14.20.6GHGuardant Health4.8619 of 5 stars4.54.00.04.34.02.50.6RDNTRadNet3.4428 of 5 stars2.71.00.04.63.32.50.0VCYTVeracyte3.8974 of 5 stars4.41.00.04.32.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGTFulgent Genetics 2.50Moderate Buy$24.0019.28% UpsideGHGuardant Health 3.05Buy$52.3225.58% UpsideRDNTRadNet 3.40Buy$69.7522.30% UpsideVCYTVeracyte 2.70Moderate Buy$40.9032.96% UpsideCurrent Analyst Ratings BreakdownLatest GH, VCYT, RDNT, and FLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025GHGuardant HealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/5/2025FLGTFulgent GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.005/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.005/1/2025GHGuardant HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $65.005/1/2025GHGuardant HealthTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $60.005/1/2025GHGuardant HealthBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$55.00 ➝ $60.005/1/2025GHGuardant HealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$53.00 ➝ $60.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGTFulgent Genetics$292.45M2.09$3.93 per share5.12$38.24 per share0.53GHGuardant Health$774.00M6.67N/AN/A$1.34 per share31.09RDNTRadNet$1.83B2.34$3.03 per share18.81$11.79 per share4.84VCYTVeracyte$463.39M5.20$0.07 per share442.29$14.30 per share2.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGTFulgent Genetics-$167.82M-$1.33N/AN/AN/A-59.39%-1.81%-1.66%8/1/2025 (Estimated)GHGuardant Health-$479.45M-$3.39N/AN/AN/A-59.05%-19,157.20%-25.96%N/ARDNTRadNet$3.04M$0.03N/A107.60N/A-0.25%4.29%1.45%N/AVCYTVeracyte-$74.40M$0.41N/A42.72N/A-2.18%3.02%2.80%N/ALatest GH, VCYT, RDNT, and FLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million2/27/2025Q4 2024RDNTRadNet$0.21$0.22+$0.01$0.07$459.42 million$477.10 million2/24/2025Q4 2024VCYTVeracyte$0.29$0.36+$0.07$0.06$110.73 million$118.63 million2/20/2025Q4 2024GHGuardant Health-$0.75-$0.90-$0.15-$0.90$192.50 million$201.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGTFulgent GeneticsN/AN/AN/AN/AN/AGHGuardant HealthN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGTFulgent GeneticsN/A4.414.41GHGuardant HealthN/A6.225.85RDNTRadNet0.892.162.16VCYTVeracyteN/A5.084.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGTFulgent Genetics48.06%GHGuardant Health92.60%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipFLGTFulgent Genetics31.76%GHGuardant Health5.50%RDNTRadNet5.12%VCYTVeracyte1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGTFulgent Genetics1,01030.44 million20.87 millionOptionableGHGuardant Health1,790123.89 million116.76 millionNot OptionableRDNTRadNet8,97075.01 million70.24 millionOptionableVCYTVeracyte79078.31 million76.49 millionOptionableGH, VCYT, RDNT, and FLGT HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Has $1.96 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 13 at 7:14 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Fred Alger Management LLCMay 13 at 6:03 AM | marketbeat.comAxa S.A. Trims Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 11 at 4:49 AM | marketbeat.comNorthern Trust Corp Has $42.34 Million Stock Position in Veracyte, Inc. (NASDAQ:VCYT)May 11 at 4:33 AM | marketbeat.comNeedham & Company LLC Cuts Veracyte (NASDAQ:VCYT) Price Target to $41.00May 11 at 3:27 AM | americanbankingnews.comVeracyte (NASDAQ:VCYT) Stock Price Down 5.8% Following Analyst DowngradeMay 11 at 1:55 AM | americanbankingnews.comBreaking Down Veracyte: 7 Analysts Share Their ViewsMay 10 at 7:33 PM | nasdaq.comVeracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting NextMay 10 at 2:33 PM | finance.yahoo.comVeracyte (NASDAQ:VCYT) Price Target Cut to $41.00 by Analysts at Needham & Company LLCMay 10 at 8:06 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Bought by Driehaus Capital Management LLCMay 10 at 7:17 AM | marketbeat.comCaption Management LLC Invests $376,000 in Veracyte, Inc. (NASDAQ:VCYT)May 10 at 5:57 AM | marketbeat.comTudor Investment Corp ET AL Sells 20,531 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 10 at 4:11 AM | marketbeat.comVeracyte (NASDAQ:VCYT) Given New $42.00 Price Target at UBS GroupMay 10 at 1:47 AM | americanbankingnews.comVeracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin UpMay 9, 2025 | zacks.comBridgeway Capital Management LLC Decreases Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 9, 2025 | marketbeat.comAQR Capital Management LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 9, 2025 | marketbeat.comWhat Makes Veracyte (VCYT) a New Buy StockMay 8, 2025 | zacks.com4VCYT : Breaking Down Veracyte: 7 Analysts Share Their ViewsMay 8, 2025 | benzinga.comCasdin Capital LLC Decreases Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 8, 2025 | marketbeat.comVeracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ExpansionsMay 8, 2025 | finance.yahoo.comBosun Asset Management LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)May 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Joby Aviation Shares Eye Breakout After Transition Flight WinBy Jeffrey Neal Johnson | April 30, 2025View Joby Aviation Shares Eye Breakout After Transition Flight WinRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsBy Ryan Hasson | May 5, 2025View Rocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsTesla Stock Eyes Breakout With Earnings on DeckBy Sam Quirke | April 16, 2025View Tesla Stock Eyes Breakout With Earnings on Deck5 Stocks That Crushed Earnings and Guidance ForecastsBy Thomas Hughes | May 8, 2025View 5 Stocks That Crushed Earnings and Guidance ForecastsGH, VCYT, RDNT, and FLGT Company DescriptionsFulgent Genetics NASDAQ:FLGT$20.12 +0.42 (+2.13%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$20.02 -0.10 (-0.49%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Guardant Health NASDAQ:GH$41.66 -0.06 (-0.14%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$42.00 +0.34 (+0.82%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.RadNet NASDAQ:RDNT$57.03 +1.29 (+2.31%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$56.62 -0.41 (-0.72%) As of 07:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$30.76 +1.05 (+3.53%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$30.33 -0.43 (-1.40%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
